The behaviourally disturbed patient with HIV/AIDS by Boyles, T & Joska, J
A 30-year-old woman presented to a rural district hos-
pital in the Eastern Cape. She was unable to give any 
history. Her family said she had recently returned from 
Cape Town. She had seemed normal on the day she 
arrived home but since then had become increasingly 
confused but with no specific complaints. Her patient 
records confirmed that she had recently completed 6 
months of TB treatment and had started antiretrovirals 
(ARVs), comprising stavudine (D4T), lamivudine (3TC) 
and efavirenz, 2 months previously. Her CD4 nadir was 
180 cells/µl. 
On examination she was apyrexial, with a pulse rate of 
120/min and a blood glucose level of 8.0 mmol/l. There 
was no meningism or clear focal neurological deficit, 
so lumbar puncture was not performed. On mental 
state examination she was found to be agitated and 
aggressive, with loud and incoherent speech; it was 
not possible to elicit delusions, but she appeared to be 
hallucinating. She gave appropriate answers to some 
simple questions and was orientated to month and 
year but not to day or date. A working diagnosis of 
psychosis secondary to HIV was made. 
The patient was sedated with haloperidol and diazepam 
and admitted for further investigation. The following 
day she remained aggressive and confused. Efavirenz 
was stopped but D4T and 3TC were continued. Over the 
next week there was gradual improvement in her men-
tal state. She became oriented to day and place, but 
complained of seeing people who were coming to steal 
her medication. Collateral history from her mother was 
that she had no known previous psychiatric history and 
that the hallucinations had started during her father’s 
funeral a week before admission.
The results of basic blood tests were normal other than 
C-reactive protein (CRP) 63.4 mg/l and platelets 67 x 
109/l.
After 1 week, the diagnosis of psychosis secondary to 
HIV was confirmed by a doctor at a tertiary level psy-
chiatric unit. The recommendation was to wean the 
patient off haloperidol and replace it with risperidone. 
Risperidone is not available at level 1 district hospi-
tals, so haloperidol 2.5 mg 3 times daily was continued. 
Nevirapine was introduced after 10 days. She was dis-
charged a week later. 
Two weeks later, having defaulted her follow-up ap-
pointment, she presented with what the admitting 
doctor described as ‘aggressive and psychotic behav-
iour’. He increased the haloperidol dose to 5 mg twice 
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While HIV invades the brain early in the course of HIV infection,1 severe mental illness probably only occurs later 
in the disease.2 In many instances this may be the first presentation of a psychiatric illness in a younger person. 
In addition, the clinical syndrome may include manic and/or psychotic features, together with neurocogni-
tive disturbance. These patients are at risk of secondary opportunistic infections or other features of systemic 




n  Where history from the patient is limited, a col-
lateral history is essential.
n  There are potentially multiple contributing caus-
es, such as HIV itself, drugs including ARVs, op-
portunistic infections including tuberculosis or a 
primary psychotic disorder.
n  It is critical to exclude delirium through careful 
clinical evaluation and targeted special investi-
gations.
INVESTIGATION
n  In a case where severe behavioural disturbance 
is present in a setting of severe immunocompro-
mise, investigations should include basic blood 
work-up, as well as lumbar puncture and a com-
puted tomography scan of the brain.
n  If confusion is prominent and/or the patient has 
a headache and/or fever, it is prudent to request 
polymerase chain reaction (PCR) testing of the 
cerebrospinal fluid for cytomegalovirus, herpes 
simplex virus, Epstein-Barr virus and JC virus.
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a day plus diazepam 5 mg at night. She claimed that 
her family were trying to kill her. She was prescribed 
fluphenazine 12.5 mg as an intramuscular injection 
and over the next week she settled and regained orien-
tation to time, person and place. Five days later, after 
much discussion with her family, she was discharged 
with a review date in 1 month.
One month later, the clinical presentation recurred. She 
was sedated with haloperidol and lorazepam and after 
consultation with an HIV psychiatrist valproate 200 mg 
bd was added. It had emerged that prominent mood 
symptoms were present, namely irritability and expan-
siveness. The persecutory delusions were paired with 
grandiosity. Over the next week she gradually improved 
and regained her orientation to time and place. Val-
proate was increased to 400 mg bd and nevirapine was 
changed back to efavirenz on the basis that stopping 
the efavirenz had had no impact on her mental state 
and there is a potential drug-drug interaction between 
valproate and nevirapine.
A week later, the patient was feeling well with no psy-
chotic symptoms and was fully orientated. She was dis-
charged with a prescription for valproate 400 mg bd. 
She has now been followed up regularly for 4 months. 
She remains completely well and is adherent to both 
her valproate and ARVs.
Neuropsychiatric presentations in late-stage HIV re-
quire clinicians to carefully exclude a range of possible 
contributory causes. One case series reported a 2% in-
cidence of new-onset psychosis in patients presenting 
with an AIDS-defining diagnosis. Of these, 50% had 
an underlying infective or metabolic cause while 50% 
were thought to have an HIV-related psychosis.3 
Infectious causes may be due to bacteria, mycobacte-
ria, viruses, fungi or spirochaetes and may form part 
of an immune reconstitution inflammatory syndrome 
(IRIS) if occurring after the onset of ARV medication. 
In the above case, the absence of fever and headache 
weighed against this possibility.
Medication-related causes of psychosis also occur. 
These include ARVs,4 antituberculosis drugs and pred-
nisone. Efavirenz is often implicated. A stepwise ap-
proach to removing potential drug causes is advised 
– treat the psychosis or mania appropriately, and if 
no response is seen, remove the most likely offending 
agent. Once the effect (or not) of this move has been 
appraised, an informed decision to make additional 
changes or switches can be made.
Primary psychiatric disorders are frequently seen in the 
setting of HIV infection. While bipolar disorder, mania 
and major depressive disorder with psychosis must all 
be considered, so too must the effects of psychosocial 
stressors such as bereavement, loss, unemployment 
and disability. Psychotropic treatments need to be used 
alongside psychosocial measures, which include edu-
cating families, addressing needs for disability grants 
and counselling.
The management of behaviourally disturbed patients 
with HIV in a remote rural hospital presents many 
challenges. One such problem is that once the diag-
nosis of HIV infection is made there is a tendency to 
attribute multiple symptoms to the HIV itself without a 
full consideration of other possibilities. While the ini-
tial probability of HIV-related psychosis may be fairly 
high in the presence of suggestive features, a definitive 
diagnosis requires the exclusion of a number of other 
possibilities. 
A similar problem is related to the treatment of all pa-
tients with psychiatric illness in this setting, namely 
that they are labelled a ‘psych patient’ without con-
sideration of which of many underlying conditions may 
be responsible for their symptoms. This situation is 
exacerbated by lack of resources. Under these condi-
tions the standard of care for patients with features 
of psychosis is monthly injectable antipsychotics with 
reliance on the patient and relatives to ensure adher-
ence. Patients with features of depression are similarly 
prescribed low-dose amitriptyline, often without a full 
explanation of time course or dose of treatment re-
quired. With more complex interventions being beyond 
the scope of the service, it is perhaps understandable 
that little attention is paid to the exact diagnosis. 
However, despite these drawbacks it is important that 
all patients are seen by a doctor at the district hospital 
and that complex cases be referred to the tertiary cen-
tre for an opinion and a follow-up plan before being 
referred back to peripheral clinics.
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n  Haloperidol is safe to use in this setting with the 
drawback of a high potential for extrapyramidal 
side-effects; atypical antipsychotics, such as ris-
peridone 0.5 - 2 mg 2 × daily or quetiapine 50 
- 200 mg 2 × daily, if available, may be better.
n  In the short term, lorazepam 2 - 4 mg 8-hourly (or 
oxazepam if liver impairment is present) may be 
used for sedation.
n  If manic symptoms are a prominent feature, con-
sider using valproate 300 mg 2 × daily, increasing 
to 600 mg 2 × daily; use lower doses and monitor 
liver function tests if liver impairment is present.
